Journal of Kerman University of Medical Sciences

Demographic and Clinical Profiles of Hemodialysis Patients Exhibiting Low PTH Levels and Adynamic Bone Disease

Document Type : Original Article

Authors

Zahra Kamiab 1, 2
Gholamreza Bazmandegan 3, 4
Fatemeh Jalali Khalilabadi 5, 6
Mohammad Khalil Salehi 7
Mahdieh Jamshidi 6, 8

1 Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

2 Department of Community Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

3 Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

4 Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

5 Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

6 Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

7 Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

8 Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

https://doi.org/10.34172/jkmu.4091
Abstract
 
 Introduction: Adynamic bone disease (ABD) is a condition that arises as a complication of chronic kidney disease, and biomarkers offer valuable insights into bone health in these patients. Parathyroid hormone (PTH) levels are commonly used as an indicator of bone turnover, with low PTH levels ( < 100 pg/mL) associated with ABD. This study described the demographic and clinical characteristics of individuals experiencing low PTH levels and evaluated the potential association between low PTH and ABD.
Methods: A cross-sectional study was conducted on 64 patients undergoing hemodialysis. The patients were divided into two groups: those with PTH levels < 100 pg/mL (n = 10) and those with PTH ≥ 100 pg/mL (n = 54). Demographic, clinical, and laboratory data, including vitamin D levels and bone biomarkers, were analyzed.
Results: Patients with reduced PTH levels demonstrated notably elevated vitamin D concentrations (P = 0.001) alongside decreased serum albumin levels (P = 0.018). No significant differences were found in other parameters, including calcium and alkaline phosphatase levels.
Conclusion: Although PTH levels are commonly used to predict bone turnover, this study acknowledges the limitation of using PTH without bone biopsy for diagnosing ABD. Additional research is required to investigate the role of vitamin D in managing ABD.

Keywords

Renal dialysis
Parathyroid hormone
Bone disease
Renal insufficiency
Chronic
Vitamin D
Subjects
  1. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison’s Principles of Internal Medicine. McGaw Hill; 2022.
  2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382(9888):260-72. doi:10.1016/ s0140-6736(13)60687-x
  3. Stats F. National Chronic Kidney Disease Fact Sheet, 2017. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2017.
  4. Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2020;75(1 Suppl 1):A6-7. doi:10.1053/j. ajkd.2019.09.003
  5. Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2017;69(3 Suppl 1):A7-8. doi:10.1053/j. ajkd.2016.12.004
  6. Seyedzadeh A, Tohidi MR, Golmohamadi S, Omrani HR, Seyedzadeh MS, Amiri S, et al. Prevalence of renal osteodystrophy and its related factors among end-stage renal disease patients undergoing hemodialysis: report from Imam Reza Referral Hospital of Medical University of Kermanshah, Iran. Oman Med J 2022;37(1):e335. doi:10.5001/omj.2021.120
  7. Raeisi Shahraki H, Kalantari S, Nafar M. Classification of chronic kidney disease patients via K-important neighbors in high dimensional metabolomics dataset. J Kerman Univ Med Sci 2019;26(3):207-13. doi:10.22062/jkmu.2019.89501
  8. Najafi I, Shakeri R, Islami F, Malekzadeh F, Salahi R, Yapan- Gharavi M, et al. Prevalence of chronic kidney disease and its associated risk factors: the first report from Iran using both microalbuminuria and urine sediment. Arch Iran Med 2012;15(2):70-5.
  9. Ghajarieh Sepanlou S, Barahimi H, Najafi I, Kamangar F, Poustchi H, Shakeri R, et al. Prevalence and determinants of chronic kidney disease in northeast of Iran: results of the Golestan cohort study. PLoS One 2017;12(5):e0176540. doi:10.1371/journal.pone.0176540
  10. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
  11. Pazianas M, Miller PD. Current understanding of mineral and bone disorders of chronic kidney disease and the scientific grounds on the use of exogenous parathyroid hormone in its management. J Bone Metab 2020;27(1):1-13. doi:10.11005/ jbm.2020.27.1.1
  12. Yagmaei B, Sandgol H, Abasnejhad M. Sunlight effect on Ca and P serum concentration and factors influencing on regulation of two lons. J Kerman Univ Med Sci 1994;1(3):133-6. [Persian].
  13. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2010;55(5):773-99. doi:10.1053/j.ajkd.2010.02.340
  14. Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T. Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis. Sci Rep 2019;9(1):6410. doi:10.1038/s41598-019-42017-z
  15. Bover J, Ureña P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I, et al. Adynamic bone disease: from bone to vessels in chronic kidney disease. Semin Nephrol 2014;34(6):626-40. doi:10.1016/j.semnephrol.2014.09.008
  16. Sun IO, Chung BH, Yoon HJ, Kim JH, Choi BS, Park CW, et al. Clinical significance of red blood cell distribution width in the prediction of mortality in patients on peritoneal dialysis. Kidney Res Clin Pract 2016;35(2):114-8. doi:10.1016/j. krcp.2016.03.003
  17. Sista SK, Arum SM. Management of adynamic bone disease in chronic kidney disease: a brief review. J Clin Transl Endocrinol 2016;5:32-5. doi:10.1016/j.jcte.2016.07.002
  18. Magbri A, El-Magbri M, Hernandez PA. Get-up and go: adynamic bone disease in chronic kidney disease patient. Arch Pharm Pract 2023;14(1):11-5. doi:10.51847/suXosREK5t
  19. Gerevich J, Ungvari GS. The description of the litigious querulant: Heinrich von Kleist’s Novella Michael Kohlhaas. Psychopathology 2015;48(2):79-83. doi:10.1159/000366562
  20. Hong YA, Kim JH, Kim YK, Chang YK, Park CW, Kim SY, et al. Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. Korean J Intern Med 2020;35(1):160-70. doi:10.3904/ kjim.2018.264
  21. Geethanjali R, Ganesh M, Jayaprakash V, Ramprasad E, Manikandan A, Rakchna M. Prevalence and biochemical profile of adynamic bone disease in a hemodialysis population. Biomedicine 2023;43(2):582-6. doi:10.51248/.v43i02.1536
  22. Nagy E, Sobh MM, Abdalbary M, Elnagar S, Elrefaey R, Shabaka S, et al. Is adynamic bone always a disease? Lessons from patients with chronic kidney disease. J Clin Med 2022;11(23):7130. doi:10.3390/jcm11237130
  23. Belluoccio D, Etich J, Rosenbaum S, Frie C, Grskovic I, Stermann J, et al. Sorting of growth plate chondrocytes allows the isolation and characterization of cells of a defined differentiation status. J Bone Miner Res 2010;25(6):1267-81. doi:10.1002/jbmr.30
  24. Fehmi H, Osman Y, Bhat S, Nguyen K, Daramola O, Cantor T, et al. Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio. Clin Nephrol 2009;71(3):267-75. doi:10.5414/cnp71267
  25. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52(3):519-30. doi:10.1053/j.ajkd.2008.03.020
  26. Wagner M, Ansell D, Kent DM, Griffith JL, Naimark D, Wanner C, et al. Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis 2011;57(6):894-902. doi:10.1053/j.ajkd.2010.12.023
  27. Phelan PJ, O’Kelly P, Walshe JJ, Conlon PJ. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail 2008;30(4):423-9. doi:10.1080/08860220801964236
  28. Wang SY, Zang XY, Fu SH, Bai J, Liu JD, Tian L, et al. Factors related to fatigue in Chinese patients with end-stage renal disease receiving maintenance hemodialysis: a multi-center cross-sectional study. Ren Fail 2016;38(3):442-50. doi:10.310 9/0886022x.2016.1138819
  29. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013;17(3):247-88. doi:10.1111/1744-9987.12058
  30. Hsiung JT, Kleine CE, Naderi N, Park C, Soohoo M, Moradi H, et al. Association of pre-end-stage renal disease serum albumin with post-end-stage renal disease outcomes among patients transitioning to dialysis. J Ren Nutr 2019;29(4):310-21. doi:10.1053/j.jrn.2018.09.004
  31. Yashiro M, Kamata T, Yamadori N, Tomita M, Muso E. Evaluation of markers to estimate volume status in hemodialysis patients: atrial natriuretic peptide, inferior vena cava diameter, blood volume changes and filtration coefficients of microvasculature. Ther Apher Dial 2007;11(2):131-7. doi:10.1111/j.1744-9987.2007.00471.x
  32. Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr 2010;20(4):243-54. doi:10.1053/j.jrn.2009.10.006
  33. Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2015;88(2):350-9. doi:10.1038/ki.2015.72
  34. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996;7(3):506-12. doi:10.1681/asn.V73506
  35. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008;74(5):655-63. doi:10.1038/ki.2008.248
  36. Evenepoel P, Opdebeeck B, David K, D’Haese PC. Bone-vascular axis in chronic kidney disease. Adv Chronic Kidney Dis 2019;26(6):472-83. doi:10.1053/j.ackd.2019.09.006
  37. Siasos G, Tousoulis D, Michalea S, Oikonomou E, Kolia C, Kioufis S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease. Curr Med Chem 2012;19(16):2555- 71. doi:10.2174/092986712800492986
  38. Sit D, Kadiroglu AK, Kayabasi H, Atay AE, Yilmaz Z, Yilmaz ME. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients. Adv Ther 2007;24(5):987-95. doi:10.1007/bf02877703
  39. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56(3):1084-93. doi:10.1046/j.1523-1755.1999.00617.x
  40. Kanno Y, Kanda E, Kato A. Methods and nutritional interventions to improve the nutritional status of dialysis patients in JAPAN-a narrative review. Nutrients 2021;13(5):1390. doi:10.3390/ nu13051390

 

Journal of Kerman University of Medical Sciences
Volume 33
Pages 1-6

Home

Editorial Board

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us